LimmaTech Biologics AG’s Post

Antimicrobial Resistance (AMR) is linked to nearly 5 million deaths annually. Without urgent action, AMR could cause 39 million deaths by 2050 (The Lancet). This growing threat occurs when microorganisms adapt to treatments, making infections harder to treat, prolonging hospital stays, increasing costs, and causing severe complications. While developing new medicines is vital, the process can be lengthy, costly, and challenging. Vaccines, however, provide a powerful solution. According to the WHO, vaccines targeting 23 pathogens could reduce antibiotic use by 22% annually, prevent hundreds of thousands of AMR-related deaths, and cut one-third of hospital costs. Tackling AMR requires global collaboration. We can protect human health and build a safer future by supporting R&D, strengthening policies, improving antimicrobial stewardship, and curbing resistance. This World Antimicrobial Resistance Awareness Week, let’s unite to raise awareness, drive innovation, and safeguard the health of future generations. #AMR #WorldAntimicrobialResistanceAwarenessWeek #Vaccines #Innovation #PhRMA Learn more here: https://lnkd.in/gWcq9uiH

HilleVax to discontinue development of norovirus vaccine for infants; shares plummet #Norovirus is one of the leading causes of vomiting, diarrhea and other foodborne illnesses. It is estimated to cause about 685 million cases and roughly 200,000 deaths globally each year, according to the World Health Organization. Low-income countries are the worst hit. #severeacutegastroenteritis I #multipleemergingtypes I #norovirusvaccine I #BiologicalProducts I #Midstagestudy Read more: https://lnkd.in/gvEWKDcD

As we conclude World Antimicrobial Resistance (AMR) Awareness Week, it is important to recognize that AMR is a significant threat to global health. It can affect individuals of any age in any country. An estimated 4.71 million deaths were associated with bacterial AMR in 2021. If not addressed, AMR could turn minor infections into serious conditions, make severe infections difficult to treat, and render many routine medical procedures risky. Antimicrobials like antibiotics are important for preventing and treating infections during surgeries and cancer treatments. However, increasing resistance to these treatments could compromise the safety of these procedures. Vaccines play an important role in preventing infections, reducing the use and misuse of antimicrobials. It is estimated that vaccines could help prevent over half a million deaths associated with AMR globally each year. For more than 175 years, Pfizer has been involved in combating infectious disease, and at Pfizer Saudi, we focus on the wellbeing of the Kingdom's people through ongoing R&D efforts and key partnerships with local medical entities to collaborate on patient support programs and educational initiatives to reduce the risk of AMR. Raising awareness and taking action against AMR remains important. Collective efforts can make a difference. #InfectiousDiseases #AntimicrobialAwareness #PfizerSaudi #CommittedToYou

▶️ NEW (10/10/24) report by the World Health Organization (WHO) "finds that vaccines against 24 pathogens could reduce the number of antibiotics needed by 22% or 2.5 billion defined daily doses globally every year, supporting worldwide efforts to address antimicrobial resistance (AMR). While some of these vaccines are already available but underused, others would need to be developed and brought to the market as soon as possible. "AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to antimicrobial medicines, making people sicker and increasing the risk of illness, death and the spread of infections that are difficult to treat. AMR is driven largely by the misuse and overuse of antimicrobials, yet, at the same time, many people around the world do not have access to essential antimicrobials. Each year, nearly 5 million deaths are associated with AMR globally. "Vaccines are an essential part of the response to reduce AMR as they prevent infections, reduce the use and overuse of antimicrobials, and slow the emergence and spread of drug-resistant pathogens." FULL REPORT AT https://lnkd.in/ggDwFRwB #infectionprevention #infectioncontrol #IPC25 #AMR #antimicrobialresistance Rob Hollis

About 7% of US Adults Have Had Long COVID, with the prevalence being higher in populations at risk of complications, according to a published article in JAMA Network Open. This study highlights the need for complementary approaches to existing vaccines and antivirals, especially in populations at risk of complications. See original article at https://lnkd.in/gweGXvp9 #longCOVID #COVID #respiratoryinfections #viralinfections #postpandemic

Abbott has introduced PneumoShield 14, a PCV-14 vaccine offering advanced protection against 14 pneumococcal strains. Designed for children over six weeks old, it enhances immunity with innovative conjugate technology, setting a new benchmark in combating severe infections. Head to our website to read more: https://lnkd.in/gXjwp9xs Abbott #indiamedtoday #abbott #healthcare #healthcarenews #healthcareupdates

Researchers at the University of Hawai'i have created a safe vaccine and immunotherapies for dual layers of protection against melioidosis infections. These new vaccines also provide post-exposure treatment for improved outcomes. #UHInnovate #Innovation #UHOIC #NewTechnology #Research

Proof-of-concept study demonstrates the use of a single dose nasal spray for the prevention of respiratory diseases. Harvard researchers engineered a neutralizing spray that coats the nasal cavity and captures large respiratory droplets, preventing infection with a large array of viruses and microbes. The researchers created a multi-modal approach to engineer a spray containing excipients identified from the FDA's list of inactive ingredient database and generally recognized as safe to maximize efficacy for each step in the multi-modal approach. With a mouse model of severe influenza infection, a single pre-exposure with the spray protected for up to 8h 100% of the animals treated with a lethal dose of the virus. The spray also reduced by more than 99.9% the viral load in the lungs of the infected animals. The authors suggest that the spray could be used as a prophylactic agent for daily use against respiratory infections. #pandemic #influenza #covid19 #health #globalhealth #publichealth #medicine #biotechnology #pharmaceuticals #FDA #WHO #CDC #ECDC #vaccines

ASCP Daily Diagnosis 07/15 CST The majority of Streptococcus pneumoniae isolates detected among children with acute otitis media were non-15- and non-20 serotypes, suggesting the impact of higher-valency pneumococcal conjugate vaccines will be limited in this population. Continued monitoring of the bacterial etiologies of acute otitis media  is vital to public health. https://lnkd.in/gJkVRmK6

🎉 A new oral cholera vaccine, Euvichol-S, has been prequalified by World Health Organization 🌍 This third addition to the vaccine family boasts a simplified formulation, potentially boosting production to help communities battling cholera outbreaks. 💉 With supplies at a low point and cases on the rise, this is a crucial step in cholera prevention and control. Learn more about this breakthrough in the fight against cholera! #PublicHealth #VaccineDevelopment 🌐